Alkermes Plc (ALKS) Expected to Post Earnings of $0.18 Per Share
Wall Street analysts expect that Alkermes Plc (NASDAQ:ALKS) will announce earnings per share (EPS) of $0.18 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Alkermes’ earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.08. Alkermes posted earnings per share of $0.15 during the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The company is scheduled to report its next quarterly earnings results on Wednesday, February 21st.
On average, analysts expect that Alkermes will report full-year earnings of $0.01 per share for the current fiscal year, with EPS estimates ranging from ($0.12) to $0.20. For the next financial year, analysts anticipate that the business will report earnings of $0.36 per share, with EPS estimates ranging from ($0.24) to $0.96. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Alkermes.
Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the prior year, the business posted ($0.09) EPS. The business’s revenue for the quarter was up 20.6% compared to the same quarter last year.
In other Alkermes news, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total transaction of $995,944.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Iain Michael Brown sold 10,652 shares of Alkermes stock in a transaction dated Saturday, December 29th. The shares were sold at an average price of $54.81, for a total value of $583,836.12. Following the transaction, the chief accounting officer now owns 16,943 shares of the company’s stock, valued at approximately $928,645.83. The disclosure for this sale can be found here. Insiders sold a total of 142,624 shares of company stock valued at $7,633,176 in the last 90 days. 5.34% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue purchased a new position in shares of Alkermes during the 4th quarter valued at about $612,000. Schwab Charles Investment Management Inc. raised its stake in shares of Alkermes by 5.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock valued at $27,011,000 after buying an additional 23,712 shares during the last quarter. Sicart Associates LLC raised its stake in shares of Alkermes by 92.3% during the 4th quarter. Sicart Associates LLC now owns 12,500 shares of the company’s stock valued at $684,000 after buying an additional 6,000 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Alkermes by 92.5% during the 4th quarter. Bank of Montreal Can now owns 13,194 shares of the company’s stock valued at $723,000 after buying an additional 6,341 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Alkermes by 6.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 41,400 shares of the company’s stock valued at $2,266,000 after buying an additional 2,400 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.
Shares of Alkermes (ALKS) opened at $57.03 on Friday. Alkermes has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $8,629.90, a price-to-earnings ratio of -51.38 and a beta of 2.13.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.